Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158792 | 1.00 | GBA1 (0.31) | GBA1 | |
| SCHEMBL6936524 | 1.00 | GBA1 (0.31) | GBA1 | |
| SCHEMBL6155840 | 1.00 | GBA1 (0.31) | GBA1 | |
| SCHEMBL10258976 | 0.82 | IDE (0.34) | — | |
| SCHEMBL7884693 | 0.82 | — | — | |
| SCHEMBL16801785 | 0.82 | — | — | |
| SCHEMBL7884469 | 0.82 | IDE (0.34) | — | |
| SCHEMBL13609345 | 0.82 | IDE (0.34) | — | |
| SCHEMBL10306469 | 0.82 | IDE (0.34) | — | |
| SCHEMBL14221957 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240110216-A1 | Production of Activated TDP-Deoxysugars in Recombinant Microorganisms | ZUCHEM INC (US) | 2024-04-04 | — | — | US | disclosed |
| US-11773423-B2 | Production of activated TDP-deoxysugars in recombinant microorganisms | ZUCHEM INC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230233620-A1 | HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES | Kanvas Biosciences, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20220249441-A1 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent Against Gram-Negative Bacteria | UNIVERSITY OF MANITOBA (CA) | 2022-08-11 | — | — | US | disclosed |
| EP-3969461-A1 | HOMODIMERIC TOBRAMYCIN ADJUVANT REPURPOSES NOVOBIOCIN AS AN EFFECTIVE ANTIBACTERIAL AGENT AGAINST GRAM-NEGATIVE BACTERIA | University of Manitoba (CA) | 2022-03-23 | — | — | EP | disclosed |
| US-10882881-B2 | C-terminal Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200283465-A1 | C-TERMINAL HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-6583119-B2 | Aromatic antibiotics such as 7-((6-deoxy-5-methyl-4-methyl-hexopyranosyl)oxy)-4-hydroxy-8-methyl-3-(1 -(phenoxyimino) ethyl)-2H-1-benzopyran-2-one (2-propynyloxy)-carbamic 3'-ester acid, for prevention of grampositive bacterial infections | AVENTIS PHARMA S.A. (FR) | 2003-06-24 | — | — | US | disclosed |
| US-6579902-B1 | Antibiotic; ethoxy-carbamic acid 3'-ester of N-(7-((6-deoxy-5-C-methyl-4-O- methyl-alpha-L-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2H-1 -benzopyran-3-yl)-benzeneacetamide | AVENTIS PHARMA S.A. (FR) | 2003-06-17 | — | — | US | disclosed |
| US-20030060609-A1 | Novel aromatic amides, preparation method and application as medicines | AVENTIS PHARMA S.A. | 2003-03-27 | — | — | US | disclosed |
| US-6420538-B1 | COMPOUND FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | disclosed |
| US-6350733-B1 | 4-HYDROXYBENZOPYRAN-2-ONE DERIVATIVES; BACTERICIDES FOR STAPHYLOCOCCUS INFECTIONS; SKIN DISORDERS | AVENTIS PHARMA S.A. (FR) | 2002-02-26 | — | — | US | disclosed |
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | AVENTIS PHARMA S.A. | 2002-01-24 | — | — | US | disclosed |
| EP-0906326-B1 | NOVEL AROMATIC DERIVATIVES SUBSTITUTED BY A RIBOSE, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | AVENTIS PHARMA SA (FR) | 2001-11-21 | — | — | EP | disclosed |
| EP-0906326-A1 | NOVEL AROMATIC DERIVATIVES SUBSTITUTED BY A RIBOSE, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | HOECHST MARION ROUSSEL (FR) | 1999-04-07 | — | — | EP | disclosed |
| EP-0894805-A1 | Ribose substituted aromatic derivatives, their preparation and use as medicaments | HOECHST MARION ROUSSEL (FR) | 1999-02-03 | — | — | EP | disclosed |
| WO-1997047634-A1 | NOVEL AROMATIC DERIVATIVES SUBSTITUTED BY A RIBOSE, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | HOECHST MARION ROUSSEL (FR) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882881-B2 | C-terminal Hsp90 inhibitors | HSP90AB2P, HSP90AB1, HSP90B1 | GBA1 1439/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | GBA1 88/4885 |
| US-20030060609-A1 | Novel aromatic amides, preparation method and application as medicines | NRDC, NPR1, NR4A1 | GBA1 2311/4885 |
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | RPIA, CD38, PARP1 | GBA1 578/4885 |
| US-20220249441-A1 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent Against Gram-Negative Bacteria | MCRS1, MYD88, MRE11 | GBA1 2386/4885 |
| US-20200283465-A1 | C-TERMINAL HSP90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90B1 | GBA1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.